The medical benefit of 5-HT research

Pharmacology Biochemistry and Behavior

Volumn 71, Issue 4, 2002, Pages 555-568

  Jones, Brian J ^a   Blackburn, Thomas P ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b H LUNDBECK A S   (Denmark)

Author keywords

5 HT receptor agonists; 5 HT receptor antagonists; 5 HT reuptake inhibitors; Therapeutic applications

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; CGS 15040A; CISPLATIN; CLOMIPRAMINE; CLOZAPINE; DERAMCICLANE FUMARATE; ELTOPRAZINE; FLUOXETINE; MAPROTILINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENELZINE; PIBOSEROD; PINDOLOL; PRUCALOPRIDE; RISPERIDONE; SERAZEPINE; SEROTONIN; SEROTONIN 1 AGONIST; SEROTONIN 1F RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TEGASEROD; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEPRESSION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; MEDICAL RESEARCH; MIGRAINE; NONHUMAN; PREMENSTRUAL DYSPHORIC DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RADIATION INDUCED EMESIS; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SOCIAL PHOBIA;

EMESIS;

EID: 0036121185     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(01)00745-6     Document Type: Review

References (153)

1. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms
2. Spinal 5-HT3 receptor mediared antinociception: Possible release of GABA
3. The hyperserotonemia of autism
4. 5-HT3 receptor antagonists and antiemesis
5. Buspirone: Future directions
6. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors
7. How does pindolol improve antidepressant action?
8. 5-HIAA in the cerebrospinal fluid: A suicide predictor?
9. Awakening the sleeping giant: Anatomy and plasticity of the brain serotonergic system
10. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agarophobia
11. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder
12. Consensus statement on posttraumatic stress disorder from the international consensus group on depression and anxiety
13. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety
14. The 5-HT1A receptor in schizophrenia: A promising target for novel atypical neuroleptics?
15. The management challenges of chronic pain: The role of antidepressants
16. A review of central 5-HT receptors and their function
17. The serotonin hypothesis of aggression revisited
18. Possible neurobiological mechanisms underlying faster onset of antidepressant actio
19. Current advances in the treatment of depression
20. Determination of the role of the 5-ht6 receptor in the rat brain: A study using antisense oligonucleotides
21. 5-ht6 receptors as emerging targets for drug discovery
22. Drug treatment of obesity
23. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls
24. New insights into the biology of schizophrenia through the mechanism of action of clozapine
25. Social phobia: Diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment
26. Role of serotonin in memory impairment
27. Autism: Current theories regarding its pathogenesis and implications for rational design
28. Agony and ecstasy: A review of MDMA effects and toxicity
29. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentialy altered in schizophrenia
30. Pharmacology and clinical experience with alosetron
31. SSRIs in the treatment of obsessive-compulsive disorder
32. 5-HT modifiers as potential treatment of asthma
33. The role of serotonin in craving: From basic research to human studies
34. 5-HT3 receptor antagonism and schizophrenia
35. 5-HT3 recptor antagonists in the treatment of cognitive disorders
36. Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?
37. Serotonergic aspects of feeding
38. The serotonergic appetite suppressant fenfluramine
39. Evidence for the existence of monoamine-containing neurons in the central nervous system: 1. Demonstration of monoamines in cell bodies of brain neurons
40. Pharmacotherapy of social anxiety disorder
41. Management of posttraumatic stress disorder: Diagnostic and therapeutic issues
42. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder
43. Eltoprazine in aggressive mentally handicapped patients: A double-blind, placebo- and baseline-controlled multi-centre study
44. Current and emerging second-generation triptans in acute migraine therapy: A comparative review
45. Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder
46. Review of current treatment in panic disorder
47. Irritable bowel syndrome. New agents targeting serotonin receptor subtypes
48. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system
49. Serotonin reuptake inhibitors in the treatment of premenstrual dysphoria
50. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome: A placebo-controlled trial
51. New drugs in the management of the irritable bowel syndrome
52. Irritable bowel syndrome: New pharmacological approaches to treatment
53. Role of 5-HT3 receptors in nociception
54. Drug treatment for PTSD. Answers and questions
55. What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy?
56. Serotonin and the heart
57. Drugs which antagonize 5-hydroxytryptamine
58. Two kinds of tryptamine receptor
59. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review
60. Advances in the pharmacotherapy of migraine. How knowledge of pathophysiology is guiding drug development
61. SSRIs in the treatment of panic disorder
62. Clinical experience with LY334370, a selective serotonin 1F receptor agonist (SSOFRA): Absence of cardiovascular effects
63. Obsessive-compulsive disorder: Diagnosis and treatment
64. Selective serotonin reuptake inhibitors in affective disorders: II. Efficacy and quality of life
65. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists
66. Pharmacology of appetite suppression
67. The neuropathology of schizophrenia. A critical review of the data and their interpretation
68. Generalized anxiety disorder. An important clinical concern
69. Serotonin autoreceptor function and antidepressant drug action
70. Generalized anxiety disorder
71. Treatment of obsessive-compulsive spectrum disorders with SSRIs
72. Serotonergic function in obsessive-compulsive disorder: Behavioral and neuroendocrine responses to oral m-CPP and fenfluramine in patients and healthy volunteers
73. 5-HT4 receptor antagonism in irritable bowel syndrome: Effect of SB-207266-A on rectal sensitivity and small bowel transit
74. Mode of action of the anti-migraine drug sumatriptan
75. Preclinical studies on the anti-migraine drug, sumatriptan
76. The therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome
77. Is there a basis for novel pharmacotherapy of autism?
78. 5-HT3 receptor antagonists in anxiety
79. The question of feedback at the somatodendritic region and antidepressant drug action
80. Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder
81. The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo controlled study
82. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States Results from the National Comorbidity Survey
83. Sibutramine - A review of clinical efficacy
84. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in dura mater
85. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder
86. Serotonergic basis of antipsychotic drug effects in schizophrenia
87. Update on the diagnosis and treatment of social anxiety disorder
88. Aggression, suicidality and serotonin
89. Association analysis of the 5-HT6 receptor polymorphism C267T with deprssion in patients with Alzheimer's disease
90. Paroxetine in the treatment of premature ejaculation
91. The role of drug therapy in social phobia
92. Antidepressants as analgesics: A review of randomized controlled trials
93. Differential occupancy of somatodendritic and postsynaptic 5-HT1A receptors by pindolol: A dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans
94. 5-HT reuptake inhibitors with 5-HT1B/1D antagonistic activity: A new approach toward efficient antidepressants
95. Long term psychiatric and cognitive effects of MDMA use
96. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: Possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists
97. 5-HT system and cognition
98. Buspirone augmentation of sertraline
99. Improving the treatment of schizophrenia: Focus on serotonin (5-HT1A) receptors
100. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: Importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat
101. The possible role of 5-HT1B/D receptors in psychiatric disorders and their potential as a target for therapy
102. Ecstasy (MDMA): A review of its possible persistent psychological efects
103. Resolution of fluoxetine-induced sexual dysfunction with the 5-HT3 antagonist granisetron
104. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: A [35]GTPgS binding study
105. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors
106. A new class of psychoactive drugs, serenics
107. 5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review
108. 5-Hydroxytryptamine 1A agonists: Potential use in glaucoma. Evidence from animal studies
109. Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation
110. Diverse signalling by 5-hydroxytryptamine (5-HT) receptors
111. Augmentation of fluoxetine's antidepressant action by pindolol: Analysis of clinical, pharmacokinetic, and methodological factors
112. Double-blind clinical trial of sertraline treatment for alcohol dependence
113. Effects of the 5-HT3 receptor antagonist GR68755 on a scopolamine-induced cognitive deficit in healthy subjects
114. 5-HT1B receptor knockout - Behavioral consequences
115. The therapeutic potential of 5-HT6 receptor antagonists
116. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist
117. Importance of h5-HT1B receptor selectivity for 5-HT terminal autoreceptor activity: An in vivo microdialysis study in the freely moving guinea pig
118. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain
119. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: Results of two controlled clinical trials
120. Effects of SSRIs on sexual function: A critical review
121. Sexual side effects of antidepressants
122. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression
123. 5-HT2C receptor activation decreases appetite and body weight in obese subjects
124. The catecholamine hypothsis of affective disorders: A review of the supporting evidence
125. Treatment of social phobia with antidepressants
126. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the atypical antipsychotics, clozapine and risperidone
127. SB-224289- a novel, selective human 5-HT1B receptor antagonist with negative intrinsic activity
128. Current concepts in the treatment of panic disorder
129. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder
130. Abnormal persistence of cerebellar serotonin1A receptors in schizophrenia suggests failure to regress in neonates
131. The analgesic effects of selective serotonin reuptake inhibitors
132. Incidence and prevalence of sexual dysfunctions: A critical review of the empirical literature
133. Evidence of early onset of antidepressant effect in randomized clinical trials
134. Control of dorsal raphe 5-HT function by multiple 5-HT1 autoreceptors: Parallel purposes or pointless plurality?
135. Diagnosis and treatment of premenstrual dysphoric disorder: An update
136. Clomipramine effectively reduces premenstrual irritability and dysphoria: A placebo-controlled trial
137. High 5-HT2A receptor occupancy in M100907-treated schizophrenic patients
138. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors
139. Triptans in migraine A comparative review of pharmacology, pharmacokinetics and efficacy
140. 5-HT7 receptors: Current knowledge and future prospects
141. Reversal of a dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin
142. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors
143. Pharmacotherapy of obsessive-compulsive disorder: Experience with selective serotonin reuptake inhibitors
144. Antidepressants in panic disorder
145. Advances in the use of 5-HT3 receptor antagonists
146. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder
147. Serotonergic receptor subtypes and hallucinogen-induced stimulus control
148. SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: Lack of tolerance and withdrawal anxiety
149. A biochemical and pharmacological suggestion about certain mental disorders
150. A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze
151. Ondansetron: A selective 5-HT3 receptor antagonist and its applications in CNS-related disorders
152. Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes
153. Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5-HT3 receptor antagonist